Reduction in Endogenous Insulin Secretion is a Risk Factor of Sarcopenia in Men with Type 2 Diabetes Mellitus

被引:0
|
作者
Ken-ichiro Tanaka
Ippei Kanazawa
Toshitsugu Sugimoto
机构
[1] Shimane University Faculty of Medicine,Department of Internal Medicine
来源
关键词
Sarcopenia; Insulin secretion; Diabetes mellitus; Skeletal muscle mass; IGF-Ι;
D O I
暂无
中图分类号
学科分类号
摘要
Sarcopenia has recently attracted widespread attention, because it increases risks of fall and bedridden. Although patients with type 2 diabetes mellitus (T2DM) are known to have lower muscle mass of limbs than healthy people, the mechanism is still unclear. We thus examined the association of muscle mass with parameters of endogenous insulin secretion such as fasting immunoreactive insulin, fasting C-peptide immunoreactivity (CPR), and daily urine CPR in 191 men with T2DM. Muscle mass of arms and legs was evaluated by dual-energy X-ray absorptiometry, and we calculated relative skeletal muscle index (RSMI), which is useful for the diagnosis of sarcopenia. Multiple regression analyses adjusted for age, duration of T2DM, serum creatinine, HbA1c, and insulin-like growth factor-I showed that each parameter of endogenous insulin was significantly and positively correlated with muscle mass of arms and legs as well as RSMI (p < 0.05). Moreover, logistic regression analyses adjusted for confounding factors mentioned above showed that each parameter of endogenous insulin was significantly lower in subjects with sarcopenia than those without it (p < 0.05). In conclusion, reduction in endogenous insulin secretion is an independent risk factor of sarcopenia in men with T2DM.
引用
收藏
页码:385 / 390
页数:5
相关论文
共 50 条
  • [1] Reduction in Endogenous Insulin Secretion is a Risk Factor of Sarcopenia in Men with Type 2 Diabetes Mellitus
    Tanaka, Ken-ichiro
    Kanazawa, Ippei
    Sugimoto, Toshitsugu
    CALCIFIED TISSUE INTERNATIONAL, 2015, 97 (04) : 385 - 390
  • [2] Type 2 diabetes mellitus is a risk factor for severe sarcopenia in elderly
    Joung, K. H.
    Kim, J. M.
    Lee, J. C.
    Kang, S. M.
    Kim, H. J.
    Ku, B. J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [3] Insulin secretion is normal in type 2 diabetes mellitus
    Ametov, A. S.
    DIABETES MELLITUS, 2007, 10 (04): : 11 - 16
  • [4] Abnormalities in insulin secretion in type 2 diabetes mellitus
    Guillausseau, P. -J.
    Meas, T.
    Virally, M.
    Laloi-Michelin, M.
    Medeau, V.
    Kevorkian, J. -P.
    DIABETES & METABOLISM, 2008, 34 : S43 - S48
  • [5] Incretins, insulin secretion and Type 2 diabetes mellitus
    T. Vilsbøll
    J. J. Holst
    Diabetologia, 2004, 47 : 357 - 366
  • [6] Incretins, insulin secretion and Type 2 diabetes mellitus
    Vilsboll, T
    Holst, JJ
    DIABETOLOGIA, 2004, 47 (03) : 357 - 366
  • [7] SARCOPENIA AND TYPE 2 DIABETES MELLITUS
    Dionyssiotis, Y.
    Athanassiou, P.
    Papathanasiou, J.
    Trovas, G.
    Kostoglou-Athanassiou, I.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S700 - S701
  • [8] Indomethacin decreases insulin secretion in type 2 diabetes mellitus
    Arias, AMP
    Romijn, JA
    Corssmit, EPM
    Ackermans, MT
    Nijpels, G
    Endert, E
    Sauerwein, HP
    DIABETOLOGIA, 1999, 42 : A153 - A153
  • [9] Role of abnormalities in insulin secretion in type 2 diabetes mellitus
    Duvillie, Bertrand
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2012, 16 (10): : 284 - 284
  • [10] Sarcopenia Is Associated With a Risk of Mortality in People With Type 2 Diabetes Mellitus
    Takahashi, Fuyuko
    Hashimoto, Yoshitaka
    Kaji, Ayumi
    Sakai, Ryosuke
    Okamura, Takuro
    Kitagawa, Noriyuki
    Okada, Hiroshi
    Nakanishi, Naoko
    Majima, Saori
    Senmaru, Takafumi
    Ushigome, Emi
    Hamaguchi, Masahide
    Asano, Mai
    Yamazaki, Masahiro
    Fukui, Michiaki
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12